J Biol Chem, Vol. 274, Issue 40, 28476-28483, October 1, 1999
The Endoplasmic Reticulum Chaperone Glycoprotein GRP94 with
Ca2+-binding and Antiapoptotic Properties Is a Novel
Proteolytic Target of Calpain during Etoposide-induced Apoptosis*
Ramachandra K.
Reddy,
Jun
Lu, and
Amy S.
Lee
From the Department of Biochemistry and Molecular Biology and the
USC/Norris Comprehensive Cancer Center, University of Southern
California School of Medicine, Los Angeles, California 90033
 |
ABSTRACT |
GRP94 is a 94-kDa chaperone glycoprotein with
Ca2+-binding properties. We report here that during
apoptosis induced by the topoisomerase II inhibitor etoposide, a
fraction of GRP94 associated with the endoplasmic reticulum membrane
undergoes specific proteolytic cleavage, coinciding with the activation
of the caspase CPP32 and initiation of DNA fragmentation. In
vivo, inhibitors of caspases able to block etoposide-induced
apoptosis can only partially protect GRP94 from proteolytic cleavage,
whereas complete inhibition is observed with calpain inhibitor I but
not with the proteasome inhibitor. In vitro, GRP94 is not a
substrate for CPP32; rather, it can be completely cleaved by calpain, a
Ca2+-regulated protease. The cleavage of GRP94 by calpain
is Ca2+-dependent and generates a discrete
polypeptide of 80 kDa. In contrast, calpain has no effect on other
stress proteins such as GRP78 or HSP70. Further, immunohistochemical
staining reveals specific co-localization of GRP94 with calpain in the
perinuclear region following etoposide treatment. We further showed
that reduction of GRP94 by antisense decreased cell viability in
etoposide-treated Jurkat cells. Our studies provide new evidence that
the cytoprotective GRP94, as in the case of the antiapoptotic protein
Bcl-2, can be targets of proteolytic cleavage themselves during the
apoptotic process.
 |
INTRODUCTION |
Programmed cell death, or "apoptosis" is a fundamental process
in multicellular organisms for normal development as well as the
maintenance of homeostasis (1). Cellular stress causes severe
constraints on numerous physiological functions, damages cellular
macromolecules and structures, and frequently leads to cell death. To
understand the in vivo regulation of apoptosis, it is
important to identify proteins that can protect cells from undergoing
cell death. As part of their program to escape host destruction, many
viruses express proteins that protect the infected cells from cell
death (2, 3). However, little is known about cellular proteins that can
confer resistance to apoptosis. To date, the best characterized
endogenous cellular proteins known to be able to inhibit apoptosis
induced by a variety of stimuli are Bcl-2, which is an integral
intracellular membrane protein, and related members of the Bcl-2/Ced9
family (4).
Cells respond to environmental or physiological stress by adaptive
changes that include the induction of a set of heat shock proteins
(HSPs)1 or the
glucose-regulated proteins (GRPs) (5-7). Depending on the target of
the stress-inducer, the HSPs and GRPs can be induced separately,
simultaneously, or reciprocally (8, 9). Evidence is emerging that these
stress proteins represent a novel class of apoptosis regulators that
when expressed at high levels can protect the host cell against cell
death (10-16). The function of the HSPs and GRPs as molecular
chaperones are well documented as they participate in protein
translocation, protein folding and assembly, and regulation of protein
secretion (17). Further, it has been proposed that the ER-localized
GRPs such as GRP94 and GRP78 with Ca2+-binding properties
(18, 19) protect cells against flux in Ca2+ homeostasis,
which could result in cell death (20-24).
Despite these significant advances, the relationship between the GRPs
and the apoptotic machinery is not known. While the central role of
mitochondria in initiating cell death has been widely studied (25), the
involvement of the ER in the apoptotic process is not well understood.
Apoptosis is triggered by the activation of several intracellular
cysteine proteases of the interleukin-converting enzyme family referred
to as caspases (26). Many of the protein targets identified so far
during apoptosis are involved in morphological and biochemical
changes that accompany programmed cell death, or in the sensing of DNA
damage and repair (27, 28). Recently, it was discovered that Bcl-2
undergoes specific proteolytic cleavage mediated by the caspases after
induction of apoptosis by Fas ligation and interleukin-3 withdrawal
(29). Strikingly, the cleavage of Bcl-2 not only inactivates its
antiapoptotic function but converts the carboxyl-terminal Bcl-2
cleavage product into a proapoptotic molecule, accelerating Sindbis
virus-induced apoptosis.
Calpains are another family of cysteine proteinases with two major
isoforms (µ- and m-calpain) that are ubiquitously expressed (30, 31).
It is believed that these cytoplasmic proteases are activated at the
cellular membranes (32). In addition to its role in platelet
aggregation, neuronal long-term potentiation, neutrophil activation,
and oocyte maturation, calpain also appears to be a necessary upstream
regulator for cell death pathways that require new protein synthesis
but not those that are independent of new protein synthesis (33). Many
putative calpain substrates are cytoskeleton-associated proteins
located at or near cellular membranes, while some are nuclear proteins
(31-33). Notably, the stability of p53, a major regulator of
apoptosis, is regulated by calpain (34). Further, Bax with proapoptotic
properties is also cleaved by calpain in cells induced to undergo
apoptosis (35). Thus, in various apoptotic models, both caspases and
calpain appear to play important roles and act on specific subsets of protein substrates.
In studying the expression of GRPs in a panel of human hematopoietic
cell lines SN and S stably transfected with wild type or mutated forms
of p53 (36), we observed a correlation between the cell's ability to
induce GRP94 and resistance to apoptosis induced by 2-deoxyglucose, a
classical inducer of GRPs, reaffirming previous observations that GRP94
possesses antiapoptotic properties (20, 23). This prompted us to
examine the status of stress proteins, in particular GRP94 and GRP78,
under apoptotic conditions other than stress conditions targeted to the
ER (8). In this report, we focus on etoposide-induced apoptosis in
three cell models: the SN cells, the human acute T cell leukemia line,
Jurkat, and the hamster fibroblast K12 cell line, where the induction of GRPs has been extensively studied (37). Fortuitously, we discovered
that GRP94, but not GRP78, is proteolytically cleaved during
etoposide-induced apoptosis. However, in vivo, only a
fraction of GRP94 appears to be accessible to calpain cleavage. Its
cleavage in vivo is completely blocked by calpain inhibitor
I and is partially inhibited by z-VAD-fmk, a general caspase inhibitor.
In in vitro assays, calpain but not CPP32 is capable of
cleavage of GRP94, with the generation of a 80-kDa carboxyl
polypeptide. The cleavage of GRP94 in vitro by calpain is
Ca2+-dependent and can be reproduced in
purified microsome preparations. In contrast, neither GRP78 nor HSP70
are substrates for calpain. We further demonstrate by laser confocal
microscopy that during etoposide-induced apoptosis, calpain becomes
co-localized with GRP94 in the perinuclear region. The cytoprotective
function of GRP94 in etoposide-treated cells is confirmed, since
transfection with an antisense vector directed against GRP94 increased
cell lethality. Our findings provide new evidence that the
antiapoptotic stress protein GRP94 is a direct target of the
apoptotic machinery. Our results are consistent with the existence
of a subpopulation of GRP94 associated with the ER membrane, where it
becomes a specific substrate for calpain cleavage concurrent with the
progression of apoptosis induced by DNA damage mediated by etoposide.
 |
EXPERIMENTAL PROCEDURES |
Cells and Culture Conditions--
The SN cell line is a human
hematopoietic cell line, HL60, stably transfected with the wild type
p53 gene (36). The human acute T cell leukemia line, Jurkat, and the SN
cells were maintained in RPMI 1640 medium supplemented with 10% fetal
calf serum containing 1% penicillin/streptomycin/neomycin antibiotics.
The K12 hamster fibroblast cell line was maintained in Dulbecco's
modified Eagle's medium containing 4.5 µg/ml glucose supplemented
with 10% fetal bovine serum and 1% antibiotics (37).
To induce apoptosis by etoposide (Calbiochem), the cells were exposed
to 30 µM etoposide for 1-10 h. To test the effect of caspase inhibitors in vivo, the cells were treated with
either 50 µM z-VAD-fmk (Calbiochem) for 2 h or 120 µM z-DEVD-fmk (Calbiochem) for 3 h. For inhibition
of calpain or proteasome activity during apoptosis, the cells were
pretreated with 45 µM calpain inhibitor I (Roche
Molecular Biochemicals) or 50 µM proteasome inhibitor N-benzyloxycarbonyl-Leu-Leu-norvalinal (Sigma) for 4 h
prior to the subsequent addition of etoposide.
Cell Lysis and Immunoblotting--
Conditions for preparation of
cell lysate and immunoblots were as described (38). Recombinant GRP78
and antisera against GRP78, GRP94, and HSP70 were purchased from
StressGen (Victoria, Canada). Antisera used were 1:1000 dilution of the
anti-GRP94 or anti-GRP78 monoclonal antibody, 1:10,000 dilution of
anti-HSP70 polyclonal antibody, 1:5000 dilution of the anti-
-actin
monoclonal antibody (Sigma), or 1:3000 dilution of the anti-CPP32
monoclonal antibody (Transduction Laboratories, Lexington, KY). The rat
anti-GRP94 antibody (SPA-850) was raised against purified chicken
GRP94. The mouse anti-GRP78 antibody (SPA-827) was raised against the SEKDEL peptide shared by ER luminal proteins. Under our experimental conditions, it recognizes most strongly GRP78 and a 45-kDa protein referred to as X, with minor but detectable reactivity toward GRP94.
Horseradish peroxidase-conjugated antibodies were used as secondary
antibodies. Rabbit anti-rat antibody (Cappel-ICN, Costa Mesa, CA) at
1:4000 dilution was used against anti-GRP94 antibody; goat anti-rabbit
antibody (StressGen) at 1:5000 dilution was used against anti-HSP70
antibody; and sheep anti-mouse antibodies (Cappel-ICN) at 1:5000
dilution were used against anti-GRP78, anti-CPP32, and anti-
-actin
antibodies. Immune complexes were detected with the ECL system
(Amersham Pharmacia Biotech), according to the manufacturer's
instructions. The bands were visualized by autoradiography and
quantitated by densitometry scanning using the Bio-Rad Imaging Densitometer.
DNA Fragmentation Assays--
5 × 106 cells
harvested at different time points of drug treatment were incubated at
37 °C in 0.5 ml of a buffer containing 10 mM Tris-HCl,
pH 8.0, 100 mM EDTA, 10 mM EGTA, 0.5% (w/v)
SDS. DNase-free RNase A was added (20 µg/ml of lysate) and incubated at 37 °C with gentle shaking, followed by the addition of proteinase K (100 µg/ml of lysate), and a further 4-h incubation at 56 °C. The DNA was extracted with phenol-chloroform and precipitated with
ethanol. Five µg of genomic DNA was loaded onto a 1.9% agarose gel.
DNA was visualized with ethidium bromide (0.5 µg/ml) under UV light.
In Vitro Proteolytic Cleavage Assay--
For
[35S]methionine-labeled GRP94, 80% confluent Jurkat
cells were labeled with 100 µCi of [35S]methionine (NEN
Life Science Products) in a 10-cm dish containing 5 ml of
methionine-free medium with 10% dialyzed fetal calf serum. After
2 h of labeling, proteins were isolated, and GRP94 protein was
immunoprecipitated as described (39). To test CPP32 and calpain
cleavage of GRP94 in vitro, 0.1 µg of recombinant CPP32 (gift of Drs. T. Rudel and G. Bokoch; Ref. 40) resuspended in 100 mM HEPES, pH 7.5, 10% sucrose, 0.1% CHAPS, 10 mM dithiothreitol, or 0.2 unit of calpain (Sigma)
resuspended in 50 mM Tris, pH 7.4, 1.5 mM
-mercaptoethanol, 5 mM CaCl2, or buffer
alone was added to the immunocomplex and kept at room temperature for
30 min. For the cleavage of recombinant GRP78, the same buffer was used with calpain added at 0.2 unit/µg of protein, and the reaction was
performed at 30 °C. The incubation was stopped by the addition of
equal volumes of 2× Laemmli buffer (1× Laemmli buffer: 50 mM Tris-HCl, pH 6.8, 2.5% (v/v)
-mercaptoethanol, 2%
SDS, 0.1% bromphenol blue, and 10% glycerol) and resolved on 8.5%
SDS-PAGE.
In other reactions, total cell lysates prepared from K12 cells were
resuspended in radioimmune precipitation buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% (v/v) Nonidet P-40, 0.5%
sodium deoxycholate, and 0.1% SDS). Calpain was added at 0.2-0.6
units/200 µg of protein with varying amounts of CaCl2,
and the reaction was performed at 30 °C. The levels of GRP94, GRP78,
HSP70, and X were probed in immunoblot assays described above.
Immunofluorescence Staining--
Fibroblast K12 cells grown in
chamber slides (Nalge Nunc International, Naperville, IL) were washed
with phosphate-buffered saline and fixed with 4% paraformaldehyde made
in phosphate-buffered saline for 10 min. For the detection of GRP94,
the cells were stained with anti-GRP94 rat monoclonal antibody (1:100
dilution) as primary antibody and the fluorescein anti-rat IgG (1:200
dilution) (Vector Laboratories Inc., Burlingame, CA) as secondary
antibody. For the detection of calpain, the cells were stained with
mouse monoclonal anti-calpain antibody (MA3-940) at 1:100 dilution
(Affinity Bioreagents, Inc., Golden, CO) and Texas Red anti-mouse IgG
antibody (1:200 dilution) (Vector Laboratories) as primary and
secondary antibodies, respectively. The stained cells were examined by
confocal laser scanning microscopy.
Isolation of Microsomes and Protease Digestion--
Conditions
for preparation of microsomes were as described (41). Essentially, K12
cells were trypsinized and after washing with cold phosphate-buffered
saline were lysed by incubation in 10 volumes of cold hypotonic buffer
(10 mM Tris-HCl, pH 7.4) and Dounce homogenization. The
lysate was immediately adjusted to 0.25 M sucrose, 1 mM MgCl2 and centrifuged at 1000 × g for 10 min at 4 °C to remove nuclei and cell debris.
The supernatant was further centrifuged at 10,000 × g
for 20 min at 4 °C. The supernatant was recentrifuged at
100,000 × g for 90 min. The pellet, representing
microsomes, was rinsed briefly with cold water and resuspended in 50 mM Tris-HCl, pH 7.4, and used for proteolytic digestion studies.
For separation of ER membranes from luminal proteins, the microsome
pellet was resuspended in 10 volumes of 100 mM sodium carbonate, pH 11.5, and incubated on ice for 30 min. The suspension was
then centrifuged for 1 h at 200,000 × g at
4 °C. The pellet, which represents ER membrane, was rinsed with cold
water and resuspended in SDS-PAGE sample loading buffer and analyzed by
Western blot. Proteins present in the ER lumen were recovered from the
supernatant by the addition of trichloroacetic acid to a final
concentration of 10%. The pellet was solubilized in the Laemmli buffer
and analyzed by Western blot.
For calpain digestion reactions, approximately 100 µg of microsomes
in 25 µl of 50 mM Tris-HCl, pH 7.4, was incubated with 0.2 unit of calpain in the presence of 5 mM
CaCl2 at 30 °C for 30 min. For trypsin digestion
reactions, the microsomes were incubated with trypsin (25 µg/ml)
either in the presence or absence of 0.5% Triton X-100 for 30 min at
30 °C. The proteolytic cleavage reactions were terminated by the
addition of Laemmli buffer and boiling at 100 °C. 10-20 µg of
total protein from each reaction was analyzed by Western blotting.
Cytotoxicity Assays--
Transfection was performed according to
the protocol for Superfect provided by Qiagen (Valencia, CA). About
7.5 × 106 Jurkat cells were seeded into 5 ml of
culture medium. An expression vector of CMV-
-galactosidase was used
as a reporter gene. It was co-transfected with either CMV-grp94-AS,
containing the antisense version of the full-length rat grp94 cDNA
driven by the CMV promoter, CMV-neo-Bcl-2 (gift of Dr. C.M. Zacharchuk,
National Institutes of Health; Ref. 42), or the CMV vector alone. After
the addition of the transfection complexes into the cells for 24 h
at 37 °C, one half of the cells were untreated and the other half
were treated with 30 µM of etoposide for 10 h. The
cells were harvested, washed with phosphate-buffered saline,
solubilized in 250 mM Tris-HCl, pH 7.5, and, following
freeze-thawing for three times, assayed for
-galactosidase activity.
The percentage cell viability was calculated by the ratio between the
amount of
-galactosidase activity remaining in the etoposide-treated
and untreated cells. For the experiments performed with the grp94
antisense vector, each dosage was repeated two to three times. The
transfection efficiency was measured by the fraction of control cells
stained positive for
-galactosidase expression. Protein extracts
were prepared from the transfected cells for measurement of GRP94
protein level by Western blots.
 |
RESULTS |
Cleavage of GRP94 during Etoposide-induced Apoptosis--
Using
the human hematopoietic cell line SN, which was stably transfected with
p53 as a model system to explore the relationship between the GRPs and
apoptosis, we tested whether the steady state levels of the GRPs were
affected during apoptosis. Exponentially growing SN cells were
incubated with etoposide and harvested at 1-h intervals for 4 h.
The onset of apoptosis was monitored by the appearance of DNA ladders
and the activation of CPP32 caspase through cleavage of its inactive
proenzyme form (Fig. 1, A and B). Concomitantly, the level of GRP94 and GRP78 were
measured by Western blot analysis (Fig. 1B). The apoptotic
process was evident after 3 h of etoposide treatment, as judged
from the DNA fragmentation pattern and the sharp disappearance of the
proenzyme form of CPP32. For GRP94 and GRP78, within the first 2 h
of drug treatment, their level was relatively constant. Strikingly, we observed that the level of GRP94, but not GRP78, started to decrease at
3 h as DNA fragmentation became evident and CPP32 was activated. Nonetheless, in contrast to CPP32, which was cleaved completely by
4 h, there appeared to be a subpopulation of GRP94 that remained resistant to this proteolytic cleavage process.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 1.
Reduction of GRP94 protein level at the onset
of etoposide-induced apoptosis. Human myeloid p53+ SN
cells were treated with 30 µM etoposide, and the cells
were harvested at hourly intervals during the treatment as indicated.
The harvested cell pellet was divided into half: one part for measuring
oligonucleosomal degradation and the other part for the Western blot
analysis. A, kinetics of DNA fragmentation. 5 µg of
genomic DNA prepared from each time point (h) as indicated at the
top was applied into a 1.9% agarose gel. B,
immunoblot analysis of CPP32, GRP94, or GRP78 protein levels during
apoptosis. The 32-kDa form of CPP32 is the proenzyme form, and the
reduction of its pro-form indicates its activation.
|
|
To determine whether this novel observation can be extended to other
cell systems, the levels of GRP94, GRP78, and
-actin were monitored
in the Jurkat human leukemia cell line, since etoposide has been shown
to induce apoptosis in these cells in a relatively short time with high
efficiency (43). Further, the same experiments were performed with K12
hamster fibroblast cells subjected to etoposide treatment. The protein
bands were quantitated by densitometry. The kinetics and magnitude of
the decrease of GRP94 protein level in the SN, Jurkat, and K12 cells
during the time course of etoposide treatment are shown in Fig.
2. For all the three cell lines, the levels of GRP78 and
-actin remained relatively constant for the whole treatment period. In contrast, in all the three cell lines, a
decrease in GRP94 level was detectable after 3 h. With SN and Jurkat cells, by 4 h, the level of GRP94 was reduced to about 40%. With K12 cells, which were more resistant to etoposide-induced cell death (data not shown), the GRP94 level was reduced to about 70%
of the untreated cells. However, in all three cell lines, a residual
amount of GRP94 remained uncleaved even after 6 h of etoposide
treatment.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
Kinetics of GRP94 proteolytic cleavage in SN
(A), Jurkat (B), and K12 cells
(C). The cells were treated with 30 µM etoposide and harvested at different time points as
indicated. From each sample, 50 µg of protein lysate was applied on a
8.5% SDS-PAGE. The protein blots were probed with antisera against
GRP94 ( ), GRP78 ( ), and -actin ( ). The relative amount of
the three proteins was quantitated and plotted against the time (h)
after etoposide treatment.
|
|
Inhibition of GRP94 Cleavage during Etoposide-induced Apoptosis
by Calpain Inhibitor--
The reduction in GRP94 protein level could
be due to selective proteolytic cleavage by proteases activated during
apoptosis. Since the activation of caspase CPP32 coincided with the
reduction in GRP94 level and most apoptotic substrates identified have
been shown to be cleaved by caspase family members (44), we first tested whether the in vivo cleavage of GRP94 is mediated by
CPP32 or its related members. For this purpose, Jurkat cells were
pretreated with caspase inhibitors prior to induction of apoptosis by
etoposide. Two caspase inhibitors were used: one set of cells were
treated with a general caspase family inhibitor, a cell-permeable
synthetic tripeptide, z-VAD-fmk, which can inhibit both caspase-1- and
caspase-3-like protease activities (45); the other set of cells were
treated with tetrapeptide z-DEVD-fmk, which is specific for the
caspase-3 (CPP32) activity (28). Our results showed that pretreatment of the cells with the general caspase inhibitor z-VAD-fmk partially prevented GRP94 cleavage during apoptosis (Fig.
3A). For cells pretreated with
z-DEVD-fmk, the cleavage of GRP94 was delayed for about 3 h;
however, by 6 h the reduction of GRP94 level was observed (Fig.
3B).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 3.
Blockage of GRP94 cleavage during apoptosis
by interleukin-converting enzyme protease family inhibitor and calpain
inhibitor in Jurkat cells. A, the cells were either
untreated (control) or pretreated with 50 µM of
interleukin-converting enzyme caspase inhibitor (z-VAD-fmk) for 2 h. The cells were then changed to fresh medium containing 30 µM etoposide, and at the indicated time points protein
lysates were prepared. B, cells pretreated with 120 µM CPP32 inhibitor (z-DEVD-fmk) for 3 h prior to
etoposide addition. C, cells pretreated with 45 µM calpain inhibitor I for 4 h prior to the addition
of etoposide. The levels of GRP94 and -actin as a loading control
were measured by Western blots.
|
|
Since GRP94 is a Ca2+-binding protein and its
phosphorylation status is also dependent on Ca2+ (39), we
tested whether the in vivo cleavage of GRP94 is sensitive to
calpain, the Ca2+-activated neutral protease associated
with the onset of apoptosis (31, 33). For this purpose, Jurkat cells
were pretreated with calpain inhibitor I (34) prior to the addition of
etoposide, and the level of GRP94 was monitored by Western blot (Fig.
3C). Our results showed that treatment of cells with calpain
inhibitor completely blocked the cleavage of GRP94 during
etoposide-induced apoptosis. Since calpain inhibitor I might also
inhibit the activity of proteasomes in addition to calpain, we tested
whether pretreatment of cells with proteasome inhibitor would prevent
GRP94 cleavage. Our results showed that in contrast to calpain
inhibitor I, pretreatment of cells with the proteasome inhibitor
N-benzyloxycarbonyl-Leu-Leu-norvalinal (LLnL) was
unable to block GRP94 cleavage (Fig.
4B). Further, the overall
protein profile remained unchanged in control cells as well as in cells
treated with etoposide in the presence or absence of calpain or
proteasome inhibitors (Fig. 4A). Collectively, these
in vivo studies reveal that the cleavage of GRP94 during etoposide-induced apoptosis appears to be selective and is not a
consequence of general protein degradation.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of calpain and proteasome inhibitors
on overall protein profile and GRP94 cleavage in etoposide-treated
cells. Jurkat cells were either untreated or pretreated with 45 µM of calpain inhibitor I or 50 µM
proteasome inhibitor N-benzyloxycarbonyl-Leu-Leu-norvalinal
(LLnL) for 4 h followed by 30 µM
etoposide treatment for another 4 h. A, total cellular
protein profile in SDS-PAGE. 25 µg of protein extract from each
sample was separated in 10% SDS-PAGE and stained by the Coomassie Blue
dye. The electrophoretic mobility of the molecular size markers
(M) is indicated at the left. B, 50 µg of protein lysate was separated in 10% SDS-PAGE, transferred to
nitrocellulose membrane, and probed with anti-GRP94 antibody. Relative
levels of GRP94 were quantitated and compared with the untreated
cells.
|
|
Ca2+-dependent Cleavage of GRP94 by
Calpain--
To test directly whether GRP94 is a substrate for
calpain, in vitro proteolytic assays were utilized.
Metabolically [35S]methionine-labeled GRP94 from Jurkat
cells was immunopurified. As shown in Fig.
5A, GRP94 was efficiently
cleaved by calpain, while two other co-immunoprecipitating protein
bands were largely unaffected. A slight increase in a band intensity
around 80 kDa was also noted. In contrast, purified recombinant CPP32,
when similarly added to radiolabeled GRP94 resulted in no cleavage of
GRP94 or the co-immunoprecipitating protein bands (Fig. 5B). Since the activity of the recombinant CPP32 was confirmed by its ability to cleave a synthetic calorimetric CPP32 substrate Ac-DEVD-pNA (data not shown), the inability of CPP32 to cleave GRP94 suggests that
GRP94 is unlikely to be a direct substrate for this caspase. Thus,
while it remains to be determined whether GRP94 is an indirect target
for CPP32 or other members of the caspase protease family can mediate
the cleavage of GRP94 during etoposide-induced apoptosis, our results
show that GRP94 is a putative substrate for calpain.

View larger version (78K):
[in this window]
[in a new window]
|
Fig. 5.
In vitro proteolytic cleavage of
metabolically-labeled GRP94. Immunopurified
[35S]methionine-labeled GRP94 was incubated with either
0.2 unit of calpain (+) or its buffer ( ) (A) or 0.1 µg
of recombinant CPP32 (+) or its buffer ( ) (B). At the end
of the reaction, the protein samples were subjected to 8.5% SDS-PAGE,
and GRP94 was detected by autoradiography. The electrophoretic mobility
of the molecular size markers is indicated at the left.
Uncleaved GRP94 is denoted by the solid arrow,
and enhanced band intensity at 80 kDa is shown by an open arrow.
|
|
Similarly, specific cleavage of GRP94 by calpain can be observed using
cell lysates prepared from K12 cells. Further, the cleavage of GRP94 by
calpain is Ca2+-dependent (Fig.
6A, lanes
3-6) and is not due to autolysis in the presence of
calcium, since omission of calpain resulted in no cleavage (Fig.
6A, lanes 1 and 2). Under
these in vitro assay conditions, GRP94 cleavage by calpain
was not detectable until a calcium concentration of 3 mM
was reached (Fig. 7A). Under
these same assay conditions, as shown by Western blot analysis using the same cell lysates, the levels of GRP78, HSP70, and a 45-kDa protein
X, which contains a KDEL epitope, were not affected by calpain, either
in the presence or absence of calcium (Fig. 6A). Further,
recombinant GRP78 was resistant to calpain cleavage, even at high
enzyme concentrations (Fig. 6B). These results confirmed that GRP94 is a specific substrate for calpain.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 6.
Specific cleavage of GRP94 by calpain.
A, K12 protein lysate was mixed with calpain (0.6 units/200
µg of protein) at different concentrations of CaCl2 and
incubated at 30 °C for 30 min. At the end of the reaction, 50 µg
of protein from each reaction was applied to 8% SDS-PAGE. The same
protein blot was probed for the levels of GRP94, GRP78, HSP70, and the
45-kDa protein X in consecutive Western blots. B, purified
recombinant GRP78 (rGRP78) was either applied to SDS-PAGE
alone (lane 1), in the reaction mixture
containing 5 mM CaCl2 in the absence of calpain
(lane 2), or with increasing amounts of calpain
as indicated (lanes 3 and 4). Samples
in lanes 2-4 were incubated at 30 °C for 30 min. 250 ng of protein was applied to each lane, and the level of GRP78
was detected by immunoblot.
|
|

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 7.
In vitro cleavage of GRP94 by
calpain is Ca2+-dependent. A,
K12 protein lysate was incubated with 0.4 unit of calpain/200 µg of
protein at different concentrations of CaCl2 as indicated.
After the reaction, the protein samples were subjected to 10% SDS-PAGE
and immunoblotted for GRP94 and X protein levels. The 80-kDa
proteolytic product of GRP94 is indicated. B, schematic
diagram of GRP94. The 94-kDa protein contains a major hydrophobic
domain, a dimerization domain, and an ER retention signal KDEL at its
carboxyl terminus. Based on the primary structure, it is postulated
that GRP94 could exist as a transmembrane protein spanning the ER lumen
and the cytoplasm (46). The putative cleavage site by calpain to
generate a 80-kDa polypeptide is indicated.
|
|
Upon resolving the proteolytic products of GRP94 in SDS-PAGE,
with the disappearance of full-length GRP94, a protein band of about 80 kDa was detected (Fig. 7A, lane 8).
Upon longer gel electrophoresis, the 80-kDa band could be further
resolved into a set of closely clustered bands (Fig. 6A,
lanes 4-6). Since the same 80-kDa polypeptide
was immunoreactive against an antibody directed against the
carboxyl-terminal KDEL epitope shared between GRP78 and GRP94 (Fig.
7B and data not shown), calpain cleavage is likely to occur
in the amino half of GRP94, generating an 80-kDa carboxyl polypeptide.
Based on the primary structure of GRP94, it is possible that a
transmembrane form of GRP94 may also exist that spans the ER membrane
and extends into the cytoplasm (Ref. 46; Fig. 7B).
Proteolytic Cleavage of GRP94 Associated with the ER
Membrane--
To test whether a fraction of GRP94 is associated with
the ER membrane, established biochemical techniques were used to
isolate the microsomes (41). The presence of GRP94 in the ER lumen and the membrane fractions was determined by Western blot analysis. As
expected, GRP94 was enriched in the microsomes as compared with the
total cell lysate (Fig. 8A,
lanes 1 and 2). In agreement with
earlier studies (41), a fraction of GRP94 was co-purified with the ER
membrane, while the majority of GRP94 was fractionated into lumen (Fig.
8A, lanes 3 and 4). Next we
determined whether GRP94 associated with the ER membrane is accessible
for proteolytic digestion. Calpain treatment of the intact microsomes
resulted in about 40% reduction of GRP94 protein level (Fig.
8B, lanes 1 and 2). Upon
longer exposure of the x-ray film, the 80-kDa proteolytic product of
GRP94 was detected after calpain treatment (Fig. 8B, lanes 3 and 4). The topology of GRP94
was further confirmed by limited trypsin digestion of the microsomes in
the presence and absence of an nonionic detergent. Prior to Triton
X-100 treatment, a fraction of GRP94 was accessible to trypsin cleavage
with the generation of proteolytic fragments of GRP94; upon disruption of the microsome by Triton X-100, GRP94 was completely digested by
trypsin (Fig. 8B, lanes 5 and
6).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 8.
Proteolytic cleavage of GRP94 in
microsomes. A, subfractionation of K12 cell lysate
(lane 1) into microsomal fractions. Isolated
microsomes (lane 2) were incubated with sodium
carbonate and subfractionated into ER membrane (lane 3) and lumen (lane 4). The amount of
GRP94 was determined by Western blotting. B, isolated
microsomes were incubated with (+) or without ( ) calpain. At the end
of the reaction, the protein samples were applied onto a 8% SDS-PAGE
and Western blotted for GRP94. The autoradiograms shown in
lanes 1 and 2 were exposed for 10 s, and in lanes 3 and 4, the exposure
time was 30 s. C, isolated microsomes were subjected to
limited trypsin digestion (25 µg/ml) either in the presence (+) or in
the absence of ( ) of 0.5% Triton X-100. At the end of the reaction,
the amount of GRP94 was detected by Western blotting. The 94-kDa GRP94
is indicated by a closed arrow, and the 80-kDa
proteolytic product (p80) is indicated by an open arrow.
|
|
Co-localization of Calpain with GRP94 following Etoposide
Treatment--
Calpain is believed to be a cytoplasmic protein that is
activated at cellular membranes. To investigate the physical
interaction of the two proteins, K12 cells treated with etoposide for
various times were immunostained with fluorescent antibodies against
calpain and GRP94 and subjected to laser confocal microscopy (Fig.
9). In control cells without etoposide
treatment, both calpain and GRP94 were detected primarily in the
perinuclear region but showed minimal co-localization. Upon treatment
of cells with etoposide, co-localization of calpain with GRP94 became
apparent. By 4 and 6 h, strong co-localization between the two
proteins in the perinuclear region was detected. In contrast, there was
no co-localization between calpain and GRP78 (data not shown). These
results suggest that, following etoposide-induced apoptosis, calpain is
activated and interacts specifically with the ER membrane-associated
GRP94.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 9.
Co-localization of GRP94 and calpain during
etoposide-induced apoptosis. K12 cells were treated with 30 µM etoposide for different times (0, 2, 4, and 6 h)
as indicated. The cells were treated with antisera against GRP94 and
calpain followed by secondary antibodies coupled with fluorescein or
Texas Red dye, respectively, and subjected to confocal laser
microscopy. Green fluorescence indicates GRP94,
red indicates calpain, and yellow indicates
co-localization of GRP94 and calpain. Phase contrast of the cell is
shown at the right.
|
|
Cytoprotective Function of GRP94 in Etoposide-treated
Cells--
To determine the consequence of reduction of GRP94 protein
level in cells undergoing etoposide-induced apoptosis, we utilized a
transient co-transfection system (42) to introduce an antisense vector
targeted against GRP94 and a
-galactosidase reporter gene into
Jurkat cells. The effect of the transiently expressed gene on apoptosis
was measured quantitatively in the transfected cell population by
assaying the
-galactosidase activity remaining in the viable,
co-transfected cells. Using Bcl-2 as a positive control, we confirmed
the earlier observation that its overexpression resulted in an increase
in cell viability in a dosage-dependent manner (42), with
complete protection achieved at the higher doses (Fig.
10A). In the case of grp94
antisense expression vector, no effect on cell viability was observed
in the control cells. Upon etoposide treatment, with increasing amounts
of the antisense vector, a dosage-dependent decrease in
cell viability was observed (Fig. 10B).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 10.
Cytotoxicity assays in etoposide-treated
Jurkat cells. A, Jurkat cells were co-transfected with
5 µg of the -galactosidase reporter plasmid and various amounts of
the CMV-Bcl-2 as indicated. The total amount of DNA was adjusted to 15 µg with the CMV empty vector in all the samples. Parallel sets of
transfected cells were either untreated or treated with 30 µM etoposide for 10 h and assayed for
-galactosidase activity. The percentage of cell viability of the
transfected cells was plotted against the amount of the Bcl-2
expression vector used in the co-transfection experiments.
B, various amounts of CMV-grp94 antisense vector (grp94 AS)
were co-transfected with the -galactosidase reporter plasmid into
Jurkat cells. The percentage of cell viability of the transfected cells
was plotted against the amount of grp94 AS used. The mean and range
were as indicated. Total cell lysate was prepared from cells
transiently transfected with the empty CMV-vector (v) or the
grp94 antisense vector (AS). The inset in
B shows Western blot of the relative amounts of GRP94
(94), with -actin (Ac) as loading
control.
|
|
To confirm the effect of the grp94 antisense vector on the GRP94
protein level, Western blot was performed using total cell lysate. A
reduction of 20% of the overall GRP94 level was observed (Fig.
10B, inset). Since the transfection efficiency
was 35%, the effective decrease in the GRP94 level in the transfected
cells was estimated to be 57%. Thus, while specific reduction of GRP94 protein level by antisense under these transient transfection conditions has no negative effect on overall cell viability, upon etoposide treatment an increase in cell death was observed.
 |
DISCUSSION |
Our investigation into the fate of the GRPs during the
apoptotic process triggered by DNA damage mediated by etoposide
reveals several unexpected and interesting results. In particular, they reveal a new relationship between GRP94, an abundant ER
stress-inducible glycoprotein associated with the ER, and calpain, a
nonlysosomal Ca2+-activated cysteine protease. This
cleavage of GRP94 upon etoposide treatment is unexpected and unique,
since under ER stress conditions mammalian cells also undergo limited
apoptosis, but GRP94 is not cleaved; rather, its level is enhanced
within several hours of ER stress treatment (8, 20, 39). In the case of
etoposide treatment, there was no immediate activation of the GRP
stress response. In addition, GRP94 was specifically cleaved within
3 h of drug treatment. While the involvement of caspases remains to be determined, we establish here that GRP94 is a specific substrate of calpain. To our knowledge, this is the first report of a
stress-inducible chaperone protein being the target of neutral cysteine
proteases during apoptosis.
Several lines of evidence suggest that GRP94 is a physiological
substrate for calpain. First, the proteolytic cleavage of GRP94 as the
cells undergo apoptosis triggered by etoposide can be observed in
several cell models in vivo. This cleavage can be completely
blocked by the calpain inhibitor I but not by proteasome inhibitor.
Second, the cleavage of GRP94 only occurs after the onset of apoptosis
when physical and functional interaction of GRP94 and calpain can be
demonstrated. Third, GRP94 as a target for calpain is demonstrated
directly in vitro and is dependent on calcium, which is an
activator of calpain protease activity. These combined results are
consistent with the hypothesis that as cells progressed through
programmed cell death triggered by etoposide, calpain is activated at
the ER membrane, where it interacts with a subpopulation of GRP94,
resulting in its specific proteolytic cleavage. In support, GRP94 was
found to exhibit properties of both a luminal protein and integral
proteins, suggesting that it could exist as two different forms within
the ER (41). Using biochemical fractionation, we also observed that a
fraction of GRP94 is associated with the ER membrane. Other
post-translational or structural changes of GRP94 could also occur
during apoptosis, making it accessible to calpain cleavage in the
cytoplasm (39, 41, 47). Further, this cleavage process is specific for
GRP94, since GRP78, another ER lumen chaperon protein also with
antiapoptotic and Ca2+-binding property and coordinately
regulated under a variety of stress conditions with GRP94 (8), is
totally unaffected under identical conditions. Furthermore, the
inability of calpain to cleave GRP78 is not due to accessibility, since
even in in vitro assay systems, GRP78 is not cleaved by
calpain. Similarly, HSP70, a stress-inducible chaperone with both
nuclear and cytoplasm localization, is not a substrate for calpain.
Since the overall protein profile is also relatively constant when
GRP94 is specifically cleaved during the apoptotic process, the
cleavage of the GRP94 by calpain is a specific event rather than a
general consequence of programmed cell death.
What are some of the unique features of GRP94 among the
stress-inducible chaperones rendering it a plausible substrate for calpain in vivo? First, GRP94 is a Ca2+-binding
protein harboring several high affinity and multiple low affinity
Ca2+-binding sites and contains several EF-hand structures
that may serve as some of the Ca2+-binding sites of the
protein (18, 48, 49). While the calcium requirements for calpain
function in vivo are not well understood, the ability of
GRP94 to sequester calcium may create a microenvironment in which its
concentration would be sufficiently high for calpain to be activated
and exert its proteolytic effect. Second, although GRP94 resides
primarily within the lumen of ER, our biochemical analysis supports
previous reports that it can also exist as a transmembrane protein with
a cytoplasmic carboxyl terminus (41, 46). Recently, GRP94 has been
found to physically and functionally interact with the cytoplasmic
Fanconi anemia group C protein (50), suggesting that some form of GRP94
is present in the cytoplasm. Thus, it is possible that as cells
progress through etoposide-induced apoptosis, calpain becomes activated
and comes into contact with a subpopulation of GRP94 associated with
the ER membrane, where cleavage of GRP94 occurs. Since the inhibitor of
cytoplasmic proteasomes cannot rescue GRP94 cleavage in
vivo, the cleavage of GRP94 in etoposide-treated cells apparently
does not utilize the retrograde system for degradation of ER luminal
proteins (51). Third, suppression of GRP94 induction has been shown to
sensitize cells in Ca2+-mediated cell death (20, 23). Here,
we showed that specific reduction of GRP94 protein level in Jurkat
cells by antisense resulted in a decrease of cell viability in
etoposide-treated cells. Thus, if activation of calpain in
etoposide-treated cells is to initiate the cell death program, it is
logical that it acts to neutralize or destroy the protective function
of antiapoptotic proteins such as GRP94, as exemplified by the cleavage
of Bcl-2 by caspase-3 (29). In case of Bcl-2, its proteolytic cleavage product is further converted into a Bax-like death effector.
Interestingly, calpains cleave their substrates in a highly specific
but limited fashion, resulting in biological active proteins (31, 32,
52). It is possible that calpain can confer its regulatory effect on
the apoptotic process by selectively cleaving and thereby activating
specific substrates, resulting in the enhancement of cell death. Thus,
it is postulated that small amounts of limited proteolysis of Bax by
calpain may be sufficient to set in motion a mitochondria-based cell
death program, which in turn controls the activation of caspases (35).
For GRP94, cleavage by calpain generates an 80-kDa subfragment in
vitro. Future studies aimed at determining the precise calpain
cleavage sites and the stability and function of the putative
proteolytic products of GRP94 will address whether calpain cleavage of
GRP94 leads to simple destruction of GRP94 or the generation of novel
biologically active molecules. Since many of the protein targets
previously identified during apoptosis are involved in the
architecture or DNA replicative components of the cell, GRP94 and Bcl-2
represent a new class of cellular targets for the apoptotic regulatory
proteases. This study provides the first evidence that a
Ca2+-binding ER protein with protective functions against
Ca2+-induced apoptosis is a substrate for a
Ca2+-activated protease. Further studies will determine
whether specific elimination of subsets of cellular proteins that
exhibit general antiapoptotic properties is a critical step in the
execution of a selective cell death program.
 |
ACKNOWLEDGEMENTS |
We thank Drs. Thomas Rudel and Gary Bokoch
for the gift of recombinant CPP32, Drs. Peter Danenberg and Axel
Schönthal for providing cell lines, Dr. Charles Zacharchuk for
the Bcl-2 expression vector, and Dr. Dwight Warren for the use of the
imaging densitometer. The confocal laser scanning microscopy was
performed at the Electron Microscopy Core Facility at the Doheny Eye
Institute, USC, supported by NEI, National Institutes of Health, Grant EY03040.
 |
FOOTNOTES |
*
This work was supported by Public Health Service Grant
CA27607 from NCI, National Institutes of Health (to A. S. L.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: USC/Norris
Comprehensive Cancer Center, MS 73, Rm. 5307, Los Angeles, CA 90089. Tel.: 323-865-0507; Fax: 323-865-0094; E-mail:
amylee@hsc.usc.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
HSP, heat
shock protein;
GRP, glucose-regulated protein;
z-VAD-fmk, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone;
z-DEVD-fmk, benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid;
PAGE, polyacrylamide gel electrophoresis;
ER, endoplasmic
reticulum;
CMV, cytomegalovirus.
 |
REFERENCES |
| 1.
|
Vaux, D. L.,
and Strasser, A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2239-2244[Abstract/Free Full Text]
|
| 2.
|
Rao, L.,
Debbas, M.,
Sabbatini, P.,
Hockenbery, D.,
Korsmeyer, S.,
and White, E.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
7742-7746[Abstract/Free Full Text]
|
| 3.
|
Crook, N. E.,
Clem, R. J.,
and Miller, L. K.
(1993)
J. Virol.
67,
2168-2174[Abstract/Free Full Text]
|
| 4.
|
Nuñez, G.,
and Clarke, M. F.
(1994)
Trends Cell Biol.
4,
399-403[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Lindquist, S.
(1986)
Annu. Rev. Biochem.
55,
1151-1191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Lee, A. S.
(1992)
Curr. Opin. Cell Biol.
4,
267-273[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Morimoto, R. I.,
Sarge, K. D.,
and Abravaya, K.
(1992)
J. Biol. Chem.
267,
21987-21990[Abstract/Free Full Text]
|
| 8.
|
Lee, A. S.
(1987)
Trends Biochem. Sci.
12,
20-23[CrossRef]
|
| 9.
|
Watowich, S. S.,
and Morimoto, R. I.
(1988)
Mol. Cell. Biol.
8,
393-405[Abstract/Free Full Text]
|
| 10.
|
Li, X. A.,
and Lee, A. S.
(1991)
Mol. Cell. Biol.
11,
3446-3453[Abstract/Free Full Text]
|
| 11.
|
Jäättelä, M.,
and Wissing, D.
(1993)
J. Exp. Med.
177,
231-236[Abstract/Free Full Text]
|
| 12.
|
Sugawara, S.,
Takeda, K.,
Lee, A.,
and Dennert, G.
(1993)
Cancer Res.
53,
6001-6005[Abstract/Free Full Text]
|
| 13.
|
Little, E.,
Ramakrishnan, M.,
Roy, B.,
Gazit, G.,
and Lee, A. S.
(1994)
Crit. Rev. Eukaryotic Gene Expression
4,
1-18[Medline]
[Order article via Infotrieve]
|
| 14.
|
Mehlen, P.,
Schulze-Osthoff, K.,
and Arrigo, A. P.
(1996)
J. Biol. Chem.
271,
16510-16514[Abstract/Free Full Text]
|
| 15.
|
Mosser, D. D.,
Caron, A. W.,
Bourget, L.,
Denis-Larose, C.,
and Massie, B.
(1997)
Mol. Cell. Biol.
17,
5317-5327[Abstract]
|
| 16.
|
McMillan, D. R.,
Xiao, X.,
Shao, L.,
Graves, K.,
and Benjamin, I. J.
(1998)
J. Biol. Chem.
273,
7523-7528[Abstract/Free Full Text]
|
| 17.
|
Hightower, L. E.
(1991)
Cell
66,
191-197[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Koch, G.,
Smith, M.,
Macer, D.,
Webster, P.,
and Mortara, R.
(1986)
J. Cell Sci.
86,
217-232[Abstract/Free Full Text]
|
| 19.
|
Lievremont, J. P.,
Rizzuto, R.,
Hendershot, L.,
and Meldolesi, J.
(1997)
J. Biol. Chem.
272,
30873-30879[Abstract/Free Full Text]
|
| 20.
|
Little, E.,
and Lee, A. S.
(1995)
J. Biol. Chem.
270,
9526-9534[Abstract/Free Full Text]
|
| 21.
|
Jamora, C.,
Dennert, G.,
and Lee, A. S.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
7690-7694[Abstract/Free Full Text]
|
| 22.
|
Liu, H.,
Bowes, R. C., III,
van de Water, B.,
Sillence, C.,
Nagelkerke, J. F.,
and Stevens, J. L.
(1997)
J. Biol. Chem.
272,
21751-21759[Abstract/Free Full Text]
|
| 23.
|
McCormick, T. S.,
McColl, K. S.,
and Distelhorst, C. W.
(1997)
J. Biol. Chem.
272,
6087-6092[Abstract/Free Full Text]
|
| 24.
|
Morris, J. A.,
Dorner, A. J.,
Edwards, C. A.,
Hendershot, L. M.,
and Kaufman, R. J.
(1997)
J. Biol. Chem.
272,
4327-4334[Abstract/Free Full Text]
|
| 25.
|
Reed, J. C.
(1997)
Cell
91,
559-562[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Porter, A. G.,
Ng, P.,
and Janicke, R. U.
(1997)
BioEssays
19,
501-507[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Li, P.,
Nijhawan, D.,
Budihardjo, I.,
Srinivasula, S. M.,
Ahmad, M.,
Alnemri, E. S.,
and Wang, X.
(1997)
Cell
91,
479-489[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Ubeda, M.,
and Habener, J. F.
(1997)
J. Biol. Chem.
272,
19562-19568[Abstract/Free Full Text]
|
| 29.
|
Cheng, E. H.,
Kirsch, D. G.,
Clem, R. J.,
Ravi, R.,
Kastan, M. B.,
Bedi, A.,
Ueno, K.,
and Hardwick, J. M.
(1997)
Science
278,
1966-1968[Abstract/Free Full Text]
|
| 30.
|
Croall, D. E.,
and DeMartino, G. N.
(1991)
Physiol. Rev.
71,
813-847[Free Full Text]
|
| 31.
|
Carafoli, E.,
and Molinari, M.
(1998)
Biochem. Biophys. Res. Commun.
247,
193-203[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Kawasaki, H.,
and Kawashima, S.
(1996)
Mol. Membr. Biol.
13,
217-224[Medline]
[Order article via Infotrieve]
|
| 33.
|
Squier, M. K.,
and Cohen, J. J.
(1997)
J. Immunol.
158,
3690-3697[Abstract]
|
| 34.
|
Kubbutat, M. H.,
and Vousden, K. H.
(1997)
Mol. Cell. Biol.
17,
460-468[Abstract]
|
| 35.
|
Wood, D. E.,
Thomas, A.,
Devi, L. A.,
Berman, Y.,
Beavis, R. C.,
Reed, J. C.,
and Newcomb, E. W.
(1998)
Oncogene
17,
1069-1078[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Banerjee, D.,
Lenz, H. J.,
Schnieders, B.,
Manno, D. J.,
Ju, J. F.,
Spears, C. P.,
Hochhauser, D.,
Danenberg, K.,
Danenberg, P.,
and Bertino, J. R.
(1995)
Cell Growth Differ.
6,
1405-1413[Abstract]
|
| 37.
|
Lee, A. S.
(1981)
J. Cell. Physiol.
106,
119-125[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Zhou, Y.,
and Lee, A. S.
(1998)
J. Natl. Cancer Inst.
90,
381-388[Abstract/Free Full Text]
|
| 39.
|
Ramakrishnan, M.,
Schönthal, A. H.,
and Lee, A. S.
(1997)
J. Cell. Physiol.
170,
115-129[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Rudel, T.,
and Bokoch, G. M.
(1997)
Science
276,
1571-1574[Abstract/Free Full Text]
|
| 41.
|
Kang, H. S.,
and Welch, W. J.
(1991)
J. Biol. Chem.
266,
5643-5649[Abstract/Free Full Text]
|
| 42.
|
Memon, S. A.,
Petrak, D.,
Moreno, M. B.,
and Zacharchuk, C. M.
(1995)
J. Immunol. Methods
180,
15-24[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Erhardt, P.,
and Cooper, G. M.
(1996)
J. Biol. Chem.
271,
17601-17604[Abstract/Free Full Text]
|
| 44.
|
Salvesen, G. S.,
and Dixit, V. M.
(1997)
Cell
91,
443-446[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Pronk, G. J.,
Ramer, K.,
Amiri, P.,
and Williams, L. T.
(1996)
Science
271,
808-810[Abstract]
|
| 46.
|
Mazzarella, R. A.,
and Green, M.
(1987)
J. Biol. Chem.
262,
8875-8883[Abstract/Free Full Text]
|
| 47.
|
Garcia, P. D.,
Ou, J.-H.,
Rutter, W. J.,
and Walter, P.
(1988)
J. Cell Biol.
106,
1093-1104[Abstract/Free Full Text]
|
| 48.
|
Van, P. N.,
Peter, F.,
and Soling, H. D.
(1989)
J. Biol. Chem.
264,
17494-17501[Abstract/Free Full Text]
|
| 49.
|
Csermely, P.,
Schnaider, T.,
Soti, C.,
Prohaszka, Z.,
and Nardai, G.
(1998)
Pharmacol. Ther.
79,
129-168[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Hoshino, T.,
Wang, J.,
Devetten, M. P.,
Iwata, N.,
Kajigaya, S.,
Wise, R. J.,
Liu, J. M.,
and Youssoufian, H.
(1998)
Blood
91,
4379-4386[Abstract/Free Full Text]
|
| 51.
|
Hiller, M. M.,
Finger, A.,
Schweiger, M.,
and Wolf, D. H.
(1996)
Science
273,
1725-1728[Abstract/Free Full Text]
|
| 52.
|
Wang, K. K.,
Villalobo, A.,
and Roufogalis, B. D.
(1989)
Biochem. J.
262,
693-706[Medline]
[Order article via Infotrieve]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Q. Lu, E. O. Harrington, J. Newton, M. Jankowich, and S. Rounds
Inhibition of ICMT Induces Endothelial Cell Apoptosis through GRP94
Am. J. Respir. Cell Mol. Biol.,
July 1, 2007;
37(1):
20 - 30.
|